Sector News

Merck KGaA appoints Allan Gabor as managing director in China

December 12, 2017
Life sciences

Merck KGaA said on Tuesday that Allan Gabor will succeed Alasdair Jelfs as managing director for the company in China as of Feb. 1, 2018.

The German company said Mr. Gabor would also take over operational responsibility for the performance materials business in China.

Additionally, Mr. Gabor will become a permanent member of the performance materials leadership team, Merck KGaA said.

Mr. Jelfs take up duties at company headquarters in Darmstadt, Germany, the company said.

Mr. Gabor joined Merck KGaA in 2013, and is currently head of the biopharma business in Asia, including China. Prior to joining the company, Mr. Gabor was head of Pfizer in China.

By Marc Navarro Gonzalez

Source: Dow Jones Newswires via Fox Business

comments closed

Related News

December 10, 2023

Brain waves found in sleep shown to protect against epileptic activity

Life sciences

Researchers from University College London (UCL) have revealed that slow brain waves that occur during sleep could protect against increased brain excitability in patients living with epilepsy. In a study published in Nature Communications, researchers placed electrodes in 25 patients living with focal epilepsy to localise abnormal activity and inform surgical treatment.

December 10, 2023

Rousselot’s soft gel capsule stabilizing technology awarded USPTO patent

Life sciences

StabiCaps gelatin formulation enhances the release of active ingredients, including medications. In May 2022, the Darling Ingredients brand also received a patent from the European Patent Office for StabiCaps for all major European countries.

December 10, 2023

Roche to acquire obesity drug maker Carmot

Life sciences

In a move to participate in the race for anti-obesity drugs, Swiss pharma giant Roche has agreed to acquire Carmot Therapeutics, a privately owned US company based in Berkeley, California. Carmot’s R&D portfolio includes clinical stage subcutaneous and oral incretins with the potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

How can we help you?

We're easy to reach